Antengene and XtalPi Announce Strategic Collaboration to Accelerate Drug Discovery Using Artificial Intelligence

SHANGHAI and HONG KONG, Dec. 16, 2021 /PRNewswire/ -- Antengene Corporation ("Antengene", Stock Code: 6996.HK), a leading innovative biopharmaceutical company dedicated to the research and commercialization of first-in-class and/or best-in-class blood and solid tumor therapies, and XtalPi, a drug discovery company revolutionizing the pharmaceutical industry with quantum physics and artificial intelligence, today jointly announced a long-term research and development collaboration.

According to the agreement,ANTENGENE CORPORATION will partner with XtalPi, leveraging XtalPi's AI-drivenAn integrated AI drug discovery and development technology platform, including in silico tools and efficient wet labs, supports ANTENGENE CORPORATION's drug discovery and development.

Dr. James Mei, Founder, Chairman and CEO of Antengene, stated: "This collaboration is another significant step for Antengene in developing first-in-class and/or best-in-class drugs for the treatment of cancer and other life-threatening diseases. We are very pleased to have the opportunity to work with XtalPi to utilize in silico methods for drug synthesis and testing. We believe that this technology platform will help us explore a broader molecular chemical space and accelerate Antengene's development efforts for novel targets."

Dr. Jian Ma, CEO of XtalPiSaid: "The strong trust between XtalPi and ANTENGENE CORPORATION lays a solid foundation for this collaboration and future long-term partnerships. I believe that XtalPi's leading AI-powered drug discovery platform will help ANTENGENE CORPORATION achieve speed and scale in new drug development that traditional methods cannot reach. The proactive collaboration between the scientists of XtalPi and ANTENGENE CORPORATION in drug research has built a win-win partnership, which is highly valuable for both parties."